BELLUS Health Announces Positive Top-Line Phase 1 Results for its Chronic Cough Drug Candidate BLU-5937
- No Taste Loss at the Anticipated Therapeutic Doses - - BLU-5937 is Shown to be Safe and Well Tolerated - - Company Intends to Initiate a Clinical Phase 2 Study in Mid-2019; Top-line Results Expected in Mid-2020 - - BELLUS Health to Host Conference Call …